Wendy Deenik

866 total citations
17 papers, 367 citations indexed

About

Wendy Deenik is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Wendy Deenik has authored 17 papers receiving a total of 367 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 9 papers in Genetics and 5 papers in Oncology. Recurrent topics in Wendy Deenik's work include Chronic Lymphocytic Leukemia Research (8 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Eosinophilic Disorders and Syndromes (4 papers). Wendy Deenik is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Eosinophilic Disorders and Syndromes (4 papers). Wendy Deenik collaborates with scholars based in Netherlands, Belgium and United States. Wendy Deenik's co-authors include Johannes L. Peterse, Bin B. R. Kroon, Wolter J. Mooi, Augustinus A. M. Hart, Emiel J. Rutgers, Jeroen J. W. M. Janssen, Jan J. Cornelissen, Bronno van der Holt, Simon Daenen and Peter J.M. Valk and has published in prestigious journals such as The Lancet, Blood and Cancer.

In The Last Decade

Wendy Deenik

17 papers receiving 365 citations

Peers

Wendy Deenik
Lauris Gastaud France
Violaine Safar France
Atsushi Shinagawa Japan
Mónica García‐Cosío Spain
Maria K. Beykirch Germany
Nikolaos Harhalakis Greece
Ricardo Alvarez United States
Christopher A. Yasenchak United States
Eisuke Shiozawa Japan
Annette Hänel Germany
Lauris Gastaud France
Wendy Deenik
Citations per year, relative to Wendy Deenik Wendy Deenik (= 1×) peers Lauris Gastaud

Countries citing papers authored by Wendy Deenik

Since Specialization
Citations

This map shows the geographic impact of Wendy Deenik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wendy Deenik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wendy Deenik more than expected).

Fields of papers citing papers by Wendy Deenik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wendy Deenik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wendy Deenik. The network helps show where Wendy Deenik may publish in the future.

Co-authorship network of co-authors of Wendy Deenik

This figure shows the co-authorship network connecting the top 25 collaborators of Wendy Deenik. A scholar is included among the top collaborators of Wendy Deenik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wendy Deenik. Wendy Deenik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Brink, Mirian, Martine E.D. Chamuleau, Rolf E. Brouwer, et al.. (2023). R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study. American Journal of Hematology. 99(2). 216–222. 11 indexed citations
2.
Vermaat, Joost S.P., Liesbeth C. de Wreede, Willem Kraan, et al.. (2019). MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis. Haematologica. 105(2). 424–434. 57 indexed citations
3.
4.
5.
Thielen, Noortje, Bronno van der Holt, Jan J. Cornelissen, et al.. (2013). Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch–Belgian Cooperative Trial for Haemato-Oncology (HOVON). European Journal of Cancer. 49(15). 3242–3246. 54 indexed citations
6.
7.
Vermeer, Henricus J., et al.. (2012). Thrombocytopenia in a nutshell. The Lancet. 379(9817). 776–776. 9 indexed citations
8.
Deenik, Wendy, et al.. (2011). An unusual case of abdominal arterial thrombosis in a young woman using desmopressin. Clinical Biochemistry. 45(1-2). 165–167. 3 indexed citations
9.
Janssen, Jeroen J. W. M., Wendy Deenik, Walter Pouwels, et al.. (2011). Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib. Leukemia. 26(5). 977–984. 23 indexed citations
10.
Deenik, Wendy, Bronno van der Holt, Jeroen J. W. M. Janssen, et al.. (2009). Polymorphisms in the Multidrug Resistance Gene MDR1 (ABCB1) Predict for Molecular Resistance in Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) Receiving High-Dose Imatinib.. Blood. 114(22). 2208–2208. 2 indexed citations
11.
Deenik, Wendy, Jeroen J. W. M. Janssen, Bronno van der Holt, et al.. (2009). Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia. Haematologica. 95(6). 914–921. 19 indexed citations
12.
Janssen, Jeroen J. W. M., Wendy Deenik, Monique Terwijn, et al.. (2009). A New Flowcytometry-Based Method to Discriminate Malignant From Normal Stem Cells in CML.. Blood. 114(22). 3245–3245. 1 indexed citations
13.
Deenik, Wendy, Bronno van der Holt, G. Verhoef, et al.. (2006). High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study. Annals of Hematology. 86(2). 117–125. 5 indexed citations
14.
Chamuleau, Martine E.D., et al.. (2003). Successful treatment of subcutaneously disseminated aspergillosis with caspofungin acetate in an allogeneic peripheral blood stem cell transplantation patient.. PubMed. 88(4). ECR10–ECR10. 1 indexed citations
15.
Deenik, Wendy, Wolter J. Mooi, Emiel J. Rutgers, et al.. (1999). Clear cell sarcoma (malignant melanoma) of soft parts. Cancer. 86(6). 969–975. 12 indexed citations
16.
Deenik, Wendy, Wolter J. Mooi, Emiel J. Rutgers, et al.. (1999). Clear cell sarcoma (malignant melanoma) of soft parts. Cancer. 86(6). 969–975. 130 indexed citations
17.
Mooi, W. J., Wendy Deenik, Johannes L. Peterse, & Pancras C.W. Hogendoorn. (1995). Keratin immunoreactivity in melanoma of soft parts (clear cell sarcoma). Histopathology. 27(1). 61–65. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lauris Gastaud Breakdown of academic impact, for papers by Violaine Safar Breakdown of academic impact, for papers by Atsushi Shinagawa Breakdown of academic impact, for papers by Mónica García‐Cosío Breakdown of academic impact, for papers by Maria K. Beykirch Breakdown of academic impact, for papers by Nikolaos Harhalakis Breakdown of academic impact, for papers by Ricardo Alvarez Breakdown of academic impact, for papers by Christopher A. Yasenchak Breakdown of academic impact, for papers by Eisuke Shiozawa Breakdown of academic impact, for papers by Annette Hänel
Rankless by CCL
2026